2seventy bio is a cell and gene therapy company focused on the research, development, and commercialization of treatments for cancer. Co. develops chimeric antigen receptor (CAR) T cell therapy for multiple myeloma. Co. is developing various clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as preclinical programs, including bbT4015, a CAR T cell therapy targeting MUC16. Additionally, Co. is developing ABECMA for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy. The TSVT YTD return is shown above.
The YTD Return on the TSVT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether TSVT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TSVT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|